Therefore, the safety of the combination therapy of PD-1/PD-L1 inhibitors and EGFR-TKI therapy in NSCLC patients remains unclear, possibly related to PD-L1 expression, tumor mutation burden (TMB), and potential differences in different tumors. This evidence concerns the gene CD274 and non-small cell lung carcinoma.